Key regulators of vascular calcification in chronic kidney disease: Hyperphosphatemia, BMP2, and RUNX2.
Humans
Core Binding Factor Alpha 1 Subunit
/ metabolism
Vascular Calcification
/ metabolism
Bone Morphogenetic Protein 2
/ metabolism
Renal Insufficiency, Chronic
/ metabolism
Hyperphosphatemia
/ metabolism
Muscle, Smooth, Vascular
/ metabolism
Cell Transdifferentiation
Osteogenesis
/ physiology
Myocytes, Smooth Muscle
/ metabolism
BMP2
Hyperphosphatemia
RUNX2
Vascular calcification secondary to chronic kidney disease
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2024
2024
Historique:
received:
26
02
2024
accepted:
19
08
2024
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
epublish
Résumé
Vascular calcification is quite common in patients with end-stage chronic kidney disease and is a major trigger for cardiovascular complications in these patients. These complications significantly impact the survival rate and long-term prognosis of individuals with chronic kidney disease. Numerous studies have demonstrated that the development of vascular calcification involves various pathophysiological mechanisms, with the osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs) being of utmost importance. High phosphate levels, bone morphogenetic protein 2 (BMP2), and runt-related transcription factor 2 (RUNX2) play crucial roles in the osteogenic transdifferentiation process of VSMCs. This article primarily reviews the molecular mechanisms by which high phosphate, BMP2, and RUNX2 regulate vascular calcification secondary to chronic kidney disease, and discusses the complex interactions among these factors and their impact on the progression of vascular calcification. The insights provided here aim to offer new perspectives for future research on the phenotypic switching and osteogenic transdifferentiation of VSMCs, as well as to aid in optimizing clinical treatment strategies for this condition, bearing significant clinical and scientific implications.
Identifiants
pubmed: 39308809
doi: 10.7717/peerj.18063
pii: 18063
pmc: PMC11416758
doi:
Substances chimiques
Core Binding Factor Alpha 1 Subunit
0
Bone Morphogenetic Protein 2
0
RUNX2 protein, human
0
BMP2 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e18063Informations de copyright
©2024 Liang et al.
Déclaration de conflit d'intérêts
The authors declare there are no competing interests.